Tag: Office of Oncologic Diseases

Office of Oncologic Diseases

Regulatory/FDA

FDA Establishes Office of Oncologic Diseases to Streamline Drug Review Process

FDA Establishes Office of Oncologic Diseases to Streamline Drug Review Process

Nov. 8, 2019 – The FDA announced this week that it has reorganized its office that reviews applications for new and existing cancer therapies; its Office of Hematology Oncology Products has been renamed the Office of Oncologic Diseases (OOD) and has six divisions to accommodate a more streamlined drug review process, according to a Nov. […]

Read more